Researcher preparing SARS-CoV-2 samples for screening in BSL-3 Core Facility at NUS Medicine Credit: NUS Yong Loo Lin School of Medicine.
Study discovered that an antibody, P36-5D2, showed a considerable reduction in contagious infection load in the lungs and brain, and minimized lung disease in lab models.
In a research study collectively performed by the Bio-Safety Level 3 (BSL-3) Core Facility at the NUS Yong Loo Lin School of Medicine (NUS Medicine) and Beijing Tsinghua University, an antibody was discovered to be capable of reducing the effects of major SARS-CoV-2 variants of issue.
As SARS-CoV-2 variations continue to emerge and spread out worldwide, vaccines and antibodies to confer potent and broad neutralizing activity are urgently required. The paper entitled “A Protective and powerful Human Neutralizing Antibody Against SARS-CoV-2 Variants,” which was first released in Frontiers in Immunology December 2021, discussed how the group isolated and defined monoclonal antibodies from people infected with SARS-CoV-2.
These anomalies, particularly N501Y, k417n, and e484k, are discovered in variations that leave from many potent neutralizing monoclonal antibodies. A single intraperitoneal injection of P36-5D2 as a prophylactic treatment demonstrated protection of the in vivo models from serious disease in the course of an infection with SARS-CoV-2 Alpha and Beta variants.
The results of P36-5D2 serve as an essential reference for the development of antibody therapies against SARS-CoV-2 and its current and emerging variations. The team is carrying out additional research to study its impacts of defense versus the infection of the Delta and Omicron variations.
” The discovery of this antibody implies we can be more positive in our battle versus COVID-19 and its variations. With a strong and recognized cooperation within NUS Medicine and Beijing Tsinghua University, our researchers would be able to improve our innovation to recognize antibodies that can potentially deal with more unidentified versions that may turn up in the future,” said Dr. Mok Chee Keng, Head, Science and Service Support Team, BSL-3 Core Facility at NUS Medicine.
Recommendation: “A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants” by Sisi Shan, Chee Keng Mok, Shuyuan Zhang, Jun Lan, Jizhou Li, Ziqing Yang, Ruoke Wang, Lin Cheng, Mengqi Fang, Zhen Qin Aw, Jinfang Yu, Qi Zhang, Xuanling Shi, Tong Zhang, Zheng Zhang, Jianbin Wang, Xinquan Wang, Justin Jang Hann Chu and Linqi Zhang, 13 December 2021, Frontiers in Immunology.DOI: 10.3389/ fimmu.2021.766821.
